WAT Waters Corporation
WAT Waters Corporation
Healthcare · Diagnostics & Research
Desk view
Market read
POC $377.87 · VWAP $362.19 · +25.3% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Coverage
2 watchlists
WAT Price Structure
Loading timeframes…
Peers
Every watchlist WAT belongs to, members best 30-day change first — WAT highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@trace-glp1-manufacturing
@biotech-capital-cycle
Reported the quarter ending 2026-07-04: revenue $1.65B, diluted EPS -$1.39, net income -$136M (SEC filing). Across the print the stock moved +6.7% (close before → first close after).
full note →Against street estimates
How WAT's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. A consensus out of line with the name's earlier estimates (opposite sign to all of them and over 3x their size) is not graded. EPS only.
Recent news
Headlines about WAT from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 10 days ago · Oct 13
- Waters Reports Strong First Quarter Following BD Biosciences and Diagnostics Acquisition
- Waters Stock Price Today | NYSE: WAT Live - Investing.com
- Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results - Waters
- Waters Corporation (NYSE: WAT) Reports First Quarter 2026 Financial Results
- Waters Q1 2026 results after BD BDS acquisition | WAT Quarterly Report (10-Q)
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
WAT research tape
48 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.